Thalidomide-4-Br

• Description :

  Thalidomide-4-Br (compound 53) is a compound with a bromodomain. Thalidomide-4-Br can be used in the research of inflammation, tumor and neurology[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Drug Derivative

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/thalidomide-4-br.html

• Purity :

  99.76

• Solubility :

  DMSO : 11.11 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3Br)=O

• Molecular Formula :

  C13H9BrN2O4

• Molecular Weight :

  337.13

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Zhou B, et al. Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2018 Jan 25;61 (2) :462-481.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [2093536-12-8]